DUBLIN , April 24, 2025 — Theravance Biopharma, Inc. (NASDAQ: TBPH) will announce its financial performance for the first quarter of 2025 and share updates on its business operations after the stock market closes on Thursday, May 8, 2025. A conference call and live webcast will be held concurrently at 5:00 pm Eastern Time (2:00 pm Pacific Time/10:00 pm Indian Standard Time) on the same day.
Conference Call Information
To join the live conference call via phone, dial (800) 715-9871 within the US or (646) 307-1963 for international participants, using Conference ID 3369474. To listen to the live conference call online, visit the Investors section of Theravance Biopharma’s website under Events and Presentations.
A replay of the webcast will be accessible on Theravance Biopharma’s website for 30 days, until June 7, 2025.
About Theravance Biopharma
Theravance Biopharma, Inc. is dedicated to providing Medicines that Make a Difference® in patients’ lives. The company utilizes its extensive experience to develop innovative therapies, including the FDA-approved YUPELRI® (revefenacin) inhalation solution, used for maintenance treatment in individuals with chronic obstructive pulmonary disease (COPD). Ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor taken once daily, is being developed for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA) and has the potential to be a first-in-class treatment addressing key symptoms in MSA patients. The Company is dedicated to building and maximizing shareholder value.
For further details, please visit .
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Other trademarks, trade names, or service marks appearing in this release belong to their respective owners.
Contact:
650-808-4045
SOURCE Theravance Biopharma, Inc.
“`